15,577 Shares in Boston Scientific Corporation $BSX Bought by Parcion Private Wealth LLC

Parcion Private Wealth LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 15,577 shares of the medical equipment provider’s stock, valued at approximately $680,000.

Several other large investors also recently modified their holdings of BSX. BlackRock Inc. bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in Boston Scientific in the 2nd quarter valued at $2,156,233,000. Jupiter Topco LLC bought a new stake in Boston Scientific in the second quarter valued at $803,357,000. Bank of America Corp DE bought a new stake in Boston Scientific in the second quarter valued at $556,026,000. Finally, Legal & General Group Plc bought a new stake in Boston Scientific in the second quarter valued at $431,890,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on BSX shares. Royal Bank Of Canada cut their price objective on Boston Scientific from $70.00 to $52.00 and set an “outperform” rating for the company in a report on Thursday. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 target price (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Leerink Partners dropped their target price on shares of Boston Scientific from $55.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday. Piper Sandler cut their price target on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, July 29th. Finally, Wells Fargo & Company reduced their price target on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $61.43.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $41.93 on Friday. The business has a fifty day moving average of $44.78 and a 200-day moving average of $56.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $105.65. The firm has a market cap of $60.77 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 1.03 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the prior year, the company earned $0.75 EPS. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities research analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 189,522 shares of company stock worth $9,157,810 over the last quarter. 0.34% of the stock is owned by company insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.